Panbela Therapeutics Overview
Latest ROE for Panbela Therapeutics: 153.59% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow153.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, PBLA shows a ROE of 153.59%. That is above the Technology sector average of 54.72%. Scroll down for historical charts and peer comparison views.
The Technology sector average ROE is about 54.72%. Panbela Therapeutics is at 153.59%, which is higher that average. That is roughly 180.7% above the sector mean. Use the comparison chart on this page to see how PBLA stacks up against individual peers as well.
Check the historical chart to see whether PBLA's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Panbela Therapeutics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Panbela Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 153.59%) with ownership activity and broader fundamentals.
The Technology average ROE is about 54.72%, while PBLA is at 153.59%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
